Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
94 results about "Cluster headache" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A series of extremely painful headaches that occur in cyclical patterns.
Methods and Compositions for Treating Migraine Pain
InactiveUS20100029665A1Benefit maximizationEliminate side effectsBiocideNervous disorderHeadache severeVascular headache
The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.
Owner:MEYERSON LAURENCE R +3
Topiramate sodium trihydrate
The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.
Owner:ORTHO MCNEIL PHARM INC
Methods and compositions for treating migraine pain
InactiveUS20060240043A1Low variabilityMaximizes therapeutic benefitBiocideBacterial antigen ingredientsHeadache severeHeadaches
The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.
Owner:NEUROMOLECULAR INC +1
Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
ActiveUS8676324B2Avoid stimulationHeart defibrillatorsMagnetotherapy using coils/electromagnetsDiseaseMedical disorder
Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.
Owner:ELECTROCORE
Ultrasound neuromodulation of the sphenopalatine ganglion
InactiveUS20110190668A1Effective treatmentUltrasonic/sonic/infrasonic diagnosticsUltrasound therapyUltrasonic sensorTransducer
Disclosed are methods and systems for non-invasive neuromodulation of the Sphenopalatine Ganglion and associated neural structures vidian nerve and / or sphenopalatine nerve using an ultrasound transducer to treat migraine and cluster headaches as well as other indications such as neurologic and psychiatric conditions. Treatment may be unilateral or bilateral.
Owner:MISHELEVICH DAVID J
Use of Anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
ActiveUS20120294802A1Reduce vasodilationInhibit and prevent photophobiaSenses disorderNervous disorderDiseaseAntibody fragments
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
Owner:UNIV OF IOWA RES FOUND +1
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N<2>-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine[BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:BOEHRINGER INGELHEIM PHARM KG
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
InactiveUS20070065463A1Improve efficiencyGood patient acceptanceBiocideBacterial antigen ingredientsMuscular spasticityTopical treatment
The invention is directed to topical formulations and methods of treating a migraines and / or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.
Owner:AFGIN PHARMA
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20090220489A1Reduce developmentDelay progressOrganic active ingredientsNervous disorderVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Benzamide derivative or salt thereof
InactiveUS20070167444A1Strong inhibitory activityBiocideNervous disorderNeurogenic painOveractive bladder
There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).
Owner:ASTELLAS PHARMA INC
Novel formulations for treatment of migraine
InactiveUS20110118189A1Immediate pharmacological effectLonger effectBiocideSenses disorderNeedle freeHeadaches
Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
Owner:ZOGENIX INC
Ultrasound neuromodulation of the occiput
Disclosed are methods and systems for non-invasive neuromodulation of the occipital nerves using ultrasound transducers to treat migraine and cluster headaches in their multiple variations as well other pain and tension conditions. Treatment may be unilateral or bilateral.
Owner:MISHELEVICH DAVID J
Topiramate salts and compositions comprising them
The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.
Owner:ORTHO MCNEIL PHARM INC
Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine
The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:BOEHRINGER INGELHEIM INT GMBH
Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
ActiveUS20150265830A1Avoid stimulationMagnetotherapy using coils/electromagnetsExternal electrodesMedical disorderNervous system
Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.
Owner:ELECTROCORE
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20150266948A1Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20150322142A1Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20120009192A1Reduce developmentDelay progressOrganic active ingredientsFungiVasomotor symptomCalcitonin
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine
The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:RUDOLF KLAUS +8
Method for treating headache with loxapine
Loxapine, amoxapine, or salts or prodrugs of either, is effective in alleviating pain, particularly headache pain such as migraine, cluster headaches and tension headaches. Preferably the loxapine or amoxapine is administered systemically, most preferably by inhalation.
Owner:ALEXZA PHARMA INC
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
InactiveUS20060183693A1Nervous disorderPeptide/protein ingredientsCo administrationAntimigraine drug
A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:BOEHRINGER INGELHEIM PHARMA KG
Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
ActiveUS20160361540A9Avoid stimulationElectrotherapyMagnetotherapy using coils/electromagnetsMedical disorderDisease
Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.
Owner:ELECTROCORE
Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
ActiveUS9708393B2Reduce vasodilationInhibit and prevent photophobiaSenses disorderNervous disorderDiseaseAntibody fragments
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
Owner:UNIV OF IOWA RES FOUND +1
Method and system for preventing migraine headaches, cluster headaches and dizziness
ActiveUS9987224B2Relieve symptomsAddressing incidenceHydroxy compound active ingredientsBacteria material medical ingredientsOral healthIntestinal microorganisms
A method and system for addressing the avoidance of migraines, cluster headaches and dizziness by adjusting an individual's microbiome, and in particular, to the provision of beneficial oral and gut microbes at particular times to enhance a person's oral health, including through the use of oral strips that adhere to surfaces in the oral cavity.
Owner:SEED HEALTH INC +1
Method and System for Preventing Migraine Headaches, Cluster Headaches and Dizziness
ActiveUS20170100329A1Relieve symptomsAddressing incidenceHydroxy compound active ingredientsBacteria material medical ingredientsOral healthIntestinal microorganisms
A method and system for addressing the avoidance of migraines, cluster headaches and dizziness by adjusting an individual's microbiome, and in particular, to the provision of beneficial oral and gut microbes at particular times to enhance a person's oral health, including through the use of oral strips that adhere to surfaces in the oral cavity.
Owner:SEED HEALTH INC +1
Topical therapy for migraine
ActiveUS8329734B2Quick treatmentRelieve symptomsBiocideNervous disorderHeadache severeTopical treatment
Owner:DEF LLC
Compositions and methods for treating headache
InactiveUS20110117070A1Eliminate side effectsMaximum efficacyBiocideNervous disorderPrevention side effectsCo administration
Compositions and methods for the treatment of headaches, such as migraine and cluster headaches, comprising co-administration of a first therapeutic component comprising topiramate and a second therapeutic component comprising a therapeutically effective amount or mixture of one or more therapeutic agents selected from the group consisting of riboflavin, magnesium, coenzyme Q10, petasin, isopetasin, and parthenolide. Also disclosed are methods for increasing the efficacy, and reducing or preventing side effects, of topiramate treatment.
Owner:AURORA SHEENA K +1
Bicyclic CB2 cannabinoid receptor ligands
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
Owner:PHARMOS
Pacap antibodies and uses thereof
ActiveUS20180362643A1Avoid adjustmentNervous disorderPharmaceutical delivery mechanismHeadachesCluster headache
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
Owner:AMGEN INC
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS9896502B2Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com